|CAS number||, (potassium salt), (sodium salt)|
|ATC code||D03,M09, R01, S01|
|Solubility in water||soluble (sodium salt)|
|S-phrases||S22, S24/25 (sodium salt)|
|LD50||> 2400 mg/kg (mouse, oral, sodium salt)
>4000 mg/kg (mouse, subcutaneous, sodium salt)
1500 mg/kg (mouse, intraperitoneal, sodium salt)
|Related compounds||D-glucuronic acid and D-N-acetylglucosamine (monomers)|
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)|
|(what is: / ?)|
Hyaluronan (also called hyaluronic acid or hyaluronate or HA) is an anionic, nonsulfated glycosaminoglycan distributed widely throughout connective, epithelial, and neural tissues. It is unique among glycosaminoglycans in that it is nonsulfated, forms in the plasma membrane instead of the Golgi, and can be very large, with its molecular weight often reaching the millions. One of the chief components of the extracellular matrix, hyaluronan contributes significantly to cell proliferation and migration, and may also be involved in the progression of some malignant tumors.
The average 70 kg (154 lb) person has roughly 15 grams of hyaluronan in the body, one-third of which is turned over (degraded and synthesized) every day. Hyaluronic acid is also a component of the group A streptococcal extracellular capsule, and is believed to play a role in virulence.
Hyaluronan has been used in attempts to treat osteoarthritis of the knee via injecting it into the joint. It has not been proven, however, to generate significant benefit and has potentially severe adverse effects.
In some cancers, hyaluronan levels correlate well with malignancy and poor prognosis. Hyaluronan is, thus, often used as a tumor marker for prostate and breast cancer. It may also be used to monitor the progression of the disease.
Hyaluronan may also be used postoperatively to induce tissue healing, notably after cataract surgery. Current models of wound healing propose the larger polymers of hyaluronic acid appear in the early stages of healing to physically make room for white blood cells, which mediate the immune response.
Hyaluronan has also been used in the synthesis of biological scaffolds for wound-healing applications. These scaffolds typically have proteins such as fibronectin attached to the hyaluronan to facilitate cell migration into the wound. This is particularly important for individuals with diabetes suffering from chronic wounds.
Until the late 1970s, hyaluronan was described as a "goo" molecule, a ubiquitous carbohydrate polymer that is part of the extracellular matrix. For example, hyaluronan is a major component of the synovial fluid, and was found to increase the viscosity of the fluid. Along with lubricin, it is one of the fluid's main lubricating components.
Hyaluronan is an important component of articular cartilage, where it is present as a coat around each cell (chondrocyte). When aggrecan monomers bind to hyaluronan in the presence of link protein, large, highly negatively charged aggregates form. These aggregates imbibe water and are responsible for the resilience of cartilage (its resistance to compression). The molecular weight (size) of hyaluronan in cartilage decreases with age, but the amount increases.
Hyaluronan is also a major component of skin, where it is involved in tissue repair. When skin is exposed to excessive UVB rays, it becomes inflamed (sunburn) and the cells in the dermis stop producing as much hyaluronan, and increase the rate of its degradation. Hyaluronan degradation products then accumulate in the skin after UV exposure.
While it is abundant in extracellular matrices, hyaluronan also contributes to tissue hydrodynamics, movement and proliferation of cells, and participates in a number of cell surface receptor interactions, notably those including its primary receptors, CD44 and RHAMM. Upregulation of CD44 itself is widely accepted as a marker of cell activation in lymphocytes. Hyaluronan's contribution to tumor growth may be due to its interaction with CD44. Receptor CD44 participates in cell adhesion interactions required by tumor cells.
Although hyaluronan binds to receptor CD44, there is evidence hyaluronan degradation products transduce their inflammatory signal through toll-like receptor 2 (TLR2), TLR4 or both TLR2, and TLR4 in macrophages and dendritic cells. TLR and hyaluronan play a role in innate immunity.
High concentrations of hyaluronan in the brains of young rats, and reduced concentrations in the brains of adult rats suggest hyaluronan plays an important role in brain development.
Hyaluronan is a polymer of disaccharides, themselves composed of D-glucuronic acid and D-N-acetylglucosamine, linked via alternating β-1,4 and β-1,3 glycosidic bonds. Hyaluronan can be 25,000 disaccharide repeats in length. Polymers of hyaluronan can range in size from 5,000 to 20,000,000 Da in vivo. The average molecular weight in human synovial fluid is 3–4 million Da, and hyaluronan purified from human umbilical cord is 3,140,000 Da.
Hyaluronan is energetically stable, in part because of the stereochemistry of its component disaccharides. Bulky groups on each sugar molecule are in sterically favored positions, whereas the smaller hydrogens assume the less-favorable axial positions.
Hyaluronan is synthesized by a class of integral membrane proteins called hyaluronan synthases, of which vertebrates have three types: HAS1, HAS2, and HAS3. These enzymes lengthen hyaluronan by repeatedly adding glucuronic acid and N-acetylglucosamine to the nascent polysaccharide as it is extruded via ABC-transporter through the cell membrane into the extracellular space.
Hyaluronan synthesis (HAS) has been shown to be inhibited by 4-methylumbelliferone (hymecromone, heparvit), a 7-hydroxy-4-methylcoumarin derivative. This selective inhibition (without inhibiting other glycosaminoglycans) may prove useful in preventing metastasis of malignant tumor cells.
Cell receptors for hyaluronan
So far, cell receptors that have been identified for HA fall into three main groups: CD44, Receptor for HA-mediated motility (RHAMM) and intercellular adhesion molecule-1 (ICAM-1). CD44 and ICAM-1 were already known as cell adhesion molecules with other recognized ligands before their HA binding was discovered.
CD44 is widely distributed throughout the body, and the formal demonstration of HA-CD44 binding was proposed by Aruffo et al. in 1990. To date, it is recognized as the main cell surface receptor for HA. CD44 mediates cell interaction with HA and the binding of the two functions as an important part in various physiologic events, such as cell aggregation, migration, proliferation and activation; cell–cell and cell–substrate adhesion; endocytosis of HA, which leads to HA catabolism in macrophages; and assembly of pericellular matrices from HA and proteoglycan. Two significant roles of CD44 in skin were proposed by Kaya et al. The first is regulation of keratinocyte proliferation in response to extracellular stimuli, and the second is the maintenance of local HA homeostasis.
ICAM-1 is known mainly as a metabolic cell surface receptor for HA, and this protein may be responsible mainly for the clearance of HA from lymph and blood plasma, which accounts for perhaps most of its whole-body turnover Ligand binding of this receptor, thus, triggers a highly coordinated cascade of events that includes the formation of an endocytotic vesicle, its fusion with primary lysosomes, enzymatic digestion to monosaccharides, active transmembrane transport of these sugars to cell sap, phosphorylation of GlcNAc and enzymatic deacetylation. Like its name, ICAM-1 may also serve as a cell adhesion molecule, and the binding of HA to ICAM-1 may contribute to the control of ICAM-1-mediated inflammatory activation.
Hyaluronan is degraded by a family of enzymes called hyaluronidases. In humans, there are at least seven types of hyaluronidase-like enzymes, several of which are tumor suppressors. The degradation products of hyaluronan, the oligosaccharides and very low-molecular-weight hyaluronan, exhibit pro-angiogenic properties. In addition, recent studies showed hyaluronan fragments, not the native high-molecular mass of hyaluronan, can induce inflammatory responses in macrophages and dendritic cells in tissue injury and in skin transplant
Skin provides a mechanical barrier to the external environment and acts to prevent the ingress of infectious agents. Once injured, the tissues beneath are exposed to infection; therefore, rapid and effective healing is of crucial significance to reconstruct a barrier function. Skin wound healing is a complex process, and includes many interacting processes initiated by haemostasis and the release of platelet-derived factors. The following stages are inflammation, granulation tissue formation, reepithelization and remodeling. HA is likely to play a multifaceted role in mediation of these cellular and matrix events. The proposed roles of HA in this sequence of skin wound healing events are elucidated in details below.
Many biological factors, such as growth factors, cytokines, eicosanoids etc., are generated in the inflammation process. These factors are necessary for the subsequent steps of wound healing due to their roles in promoting migration of inflammatory cells, fibroblasts, and endothelial cells into the wound site.
The wound tissue in the early inflammatory phase of wound repair is abundant in HA, probably a reflection of increased synthesis. HA acts as a promoter of early inflammation, which is crucial in the whole skin wound-healing process. In a murine air pouch model of carrageenan/IL-1-induced inflammation, HA was observed to enhance cellular infiltration. Kobayashi and colleagues showed a dose-dependent increase of the proinflammatory cytokines TNF-α and IL-8 production by human uterine fibroblasts at HA concentrations of 10μg/ml to 1 mg/ml via a CD44-mediated mechanism. Endothelial cells, in response to inflammatory cytokines such as TNF-α, and bacterial lipopolysaccharide, also synthesize HA, which has been shown to facilitate primary adhesion of cytokine-activated lymphocytes expressing the HA-binding variants of CD44 under laminar and static flow conditions. It is interesting to note that HA has contradictory dual functions in the inflammatory process. It not only can promote the inflammation, as stated above, but also can moderate the inflammatory response, which may contribute to the stabilization of granulation tissue matrix, as described in the following part.
- Granulation and organization of the granulation tissue matrix
Granulation tissue is the perfused, fibrous connective tissue that replaces a fibrin clot in healing wounds. It typically grows from the base of a wound and is able to fill wounds of almost any size it heals. HA is abundant in granulation tissue matrix. A variety of cell functions that are essential for tissue repair may attribute to this HA-rich network. These functions include facilitation of cell migration into the provisional wound matrix, cell proliferation and organization of the granulation tissue matrix. Initiation of inflammation is crucial for the formation of granulation tissue, therefore the pro-inflammatory role of HA as discussed above also contributes to this stage of wound healing.
- HA and cell migration
Cell migration is essential for the formation of granulation tissue. The early stage of granulation tissue is dominated by a HA-rich extracellular matrix, which is regarded as a conducive environment for migration of cells into this temporary wound matrix. Contributions of HA to cell migration may attribute to its physicochemical properties as stated above, as well as its direct interactions with cells. For the former scenario, HA provides an open hydrated matrix that facilitates cell migration, whereas, in the latter scenario, directed migration and control of the cell locomotory mechanisms are mediated via the specific cell interaction between HA and cell surface HA receptors. As discussed before, the three principal cell surface receptors for HA are CD44, RHAMM, and ICAM-1. RHAMM is more related to cell migration. It forms links with several protein kinases associated with cell locomotion, for example, extracellular signal-regulated protein kinase (ERK), p125fak, and pp60c-src. During fetal development, the migration path through which neural crest cells migrate is rich in HA. HA is closely associated with the cell migration process in granulation tissue matrix, and studies show that cell movement can be inhibited, at least partially, by HA degradation or blocking HA receptor occupancy.
By providing the dynamic force to the cell, HA synthesis has also been shown to associate with cell migration. Basically, HA is synthesized at the plasma membrane and released directly into the extracellular environment. This may contribute to the hydrated microenvironment at sites of synthesis, and is essential for cell migration by facilitating cell detachment.
- Role of HA in moderation of the inflammatory response
Although inflammation is an integral part of granulation tissue formation, for normal tissue repair to proceed, inflammation needs to be moderated. The initial granulation tissue formed is highly inflammatory with a high rate of tissue turnover mediated by matrix degrading enzymes and reactive oxygen metabolites that are products of inflammatory cells. Stabilization of granulation tissue matrix can be achieved by moderating inflammation. HA functions as an important moderator in this moderation process, which contradicts its role in inflammatory stimulation, as described above. HA can protect against free-radical damage to cells. This may attribute to its free-radical scavenging property, a physicochemical characteristic shared by large polyionic polymers. In a rat model of free-radical scavenging property investigated by Foschi D. and colleagues, HA has been shown to reduce damage to the granulation tissue.
In addition to the free-radical scavenging role, HA may also function in the negative feedback loop of inflammatory activation through its specific biological interactions with the biological constituents of inflammation. TNF-α, an important cytokine generated in inflammation, stimulates the expression of TSG-6 (TNF-stimulated gene 6) in fibroblasts and inflammatory cells. TSG-6, a HA-binding protein, also forms a stable complex with the serum proteinase inhibitor IαI (Inter-α-inhibitor) with a synergistic effect on the latter’s plasmin-inhibitory activity. Plasmin is involved in activation of the proteolytic cascade of matrix metalloproteinases and other proteinases leading to inflammatory tissue damage. Therefore, the action of TSG-6/ IαI complex, which may be additionally organized by binding to HA in the extracellular matrix, may serve as a potent negative feedback loop to moderate inflammation and stabilize the granulation tissue as healing progresses. In the murine air pouch model of carragenan/IL-1 (Interleukin-1β)-induced inflammation, where HA has been shown to have a proinflammatory property, reduction of inflammation can be achieved by administrating TSG-6, and the result is comparable with systemic dexamethasone treatment.
HA plays an important role in the normal epidermis. HA also has crucial functions in the reepithelization process due to several of its properties. It serves as an integral part of the extracellular matrix of basal keratinocytes, which are major constituents of the epidermis; its free-radical scavenging function and its role in keratinocyte proliferation and migration.
In normal skin, HA is found in relative high concentrations in the basal layer of the epidermis where proliferating keratinocytes are found. CD44 is collocated with HA in the basal layer of epidermis where additionally it has been shown to be preferentially expressed on plasma membrane facing the HA-rich matrix pouches. Maintaining the extracellular space and providing an open, as well as hydrated, structure for the passage of nutrients are the main functions of HA in epidermis. Tammi R. and other colleagues found HA content increases at the presence of retinoic acid (vitamin A). The proposed effects of retinoic acid against skin photo-damage and aging may be correlated, at least in part, with an increase of skin HA content, giving rise to increase of tissue hydration. It has been suggested the free-radical scavenging property of HA contributes to protection against solar radiation, supporting the role of CD44 acting as a HA receptor in the epidermis.
Epidermal HA also functions as a manipulator in the process of keratinocyte proliferation, which is essential in normal epidermal function, as well as during reepithelization in tissue repair. In the wound healing process, HA is expressed in the wound margin, in the connective tissue matrix, and collocating with CD44 expression in migrating keratinocytes. Kaya et al. found suppression of CD44 expression by an epidermis-specific antisense transgene resulted in animals with defective HA accumulation in the superficial dermis, accompanied by distinct morphologic alterations of basal keratinocytes and defective keratinocyte proliferation in response to mitogen and growth factors. Decrease in skin elasticity, impaired local inflammatory response, and impaired tissue repair were also observed. Their observations are strongly supportive of the important roles HA and CD44 have in skin physiology and tissue repair.
- Fetal wound healing and scarring
Lack of fibrous scarring is the primary feature of fetal wound healing. Even for longer periods, HA content in fetal wounds is still higher than that in adult wounds, which suggests that HA may, at least in part, reduce collagen deposition and therefore lead to reduced scarring. This suggestion is in agreement with the research of West et al., who showed in adult and late gestation fetal wound healing, removal of HA results in fibrotic scarring.
Role in cancer metastasis
Hyaluronan synthases (HAS) play roles in all of the stages of cancer metastasis. By producing anti-adhesive HA, HAS can allow tumor cells to release from the primary tumor mass, and if HA associates with receptors such as CD44, the activation of Rho GTPases can promote epithelial-mesenchymal transition (EMT) of the cancer cells. During the processes of intravasation or extravasation, the interaction of HAS produced HA with receptors such as CD44 or RHAMM promote the cell changes that allow for the cancer cells to infiltrate the vascular or lymphatic systems. While traveling in these systems, HA produced by HAS protects the cancer cell from physical damage. Finally, in the formation of a metastatic lesion, HAS produces HA to allow the cancer cell to interact with native cells at the secondary site and to produce a tumor for itself.
Hyaluronidases (HAase or HYAL) also play many roles in cancer metastasis. By helping to degrade the extracellular matrix surrounding the tumor, hyaluronidases help the cancer cell escape from the primary tumor mass and play a major role in intravasation by allowing degradation of the basement membrane of the lymph or blood vessel. Hyaluronidases again play these roles in establishment of a metastatic lesion by helping with extravasation and clearing the extracellular matrix (ECM) of the secondary site. Finally, hyaluronidases play a key role in the process of angiogenesis. HA fragments promote angiogenesis and hyaluronidases produce these fragments. Interestingly, hypoxia also increases production of HA and activity of hyaluronidases.
The hyaluronan receptors, CD44 and RHAMM, are most thoroughly studied in terms of their roles in cancer metastasis. Increased clinical CD44 expression has been positively correlated to metastasis in a number of tumor types. In terms of mechanics, CD44 affects adhesion of cancer cells to each other and to endothelial cells, rearranges the cytoskeleton through the Rho GTPases, and increases the activity of ECM degrading enzymes. Increased RHAMM expression has also been clinically correlated with cancer metastasis. In terms of mechanics, RHAMM promotes cancer cell motility through a number of pathways including focal adhesion kinase (FAK), Map kinase (MAPK), pp60(c-src), and the downstream targets of Rho kinase (ROK). RHAMM can also cooperate with CD44 to promote angiogenesis toward the metastatic lesion.
Hyaluronan is a common ingredient in skin-care products.
Until recently, hyaluronic acid fillers were injected using a classic sharp hypodermic needle, cutting through nerves and vessels, causing pain and bruising. In 2009, a new technique was developed in which the skin is punctured with a sharp needle, but then a blunt-tip microcannula is slid under the skin rather than puncturing more deeply.
One study showed that a minimal surgery procedure using hyaluronic acid is an "effective and safe method for improving acne scars." Another found that this treatment can reduce the appearance of neck wrinkles. When used in combination with pimecrolimus cream, it has been shown to work well in the treatment of atopic dermatitis with no side effects. However, one peer-reviewed article presented case studies that suggest that such side effects as necrosis can occur when using hyaluronic acid injections.
Hyaluronan is used in treatment of articular disorders in horses, in particular those in competition or heavy work. It is indicated for carpal and fetlock joint dysfunctions, but not when joint sepsis or fracture are suspected. It is especially used for synovitis associated with equine osteoarthritis. It can be injected directly into an affected joint, or intravenously for less localized disorders. It may cause mild heating of the joint if directly injected, but this does not affect the clinical outcome. Intra-articularly administered medicine is fully metabolized in less than a week.
Note that, according to Canadian regulation, hyaluronan in HY-50 preparation should not be administered to animals to be slaughtered for horse meat. In Europe, however, the same preparation is not considered to have any such effect, and edibility of the horse meat is not affected.
Hyaluronan is found in many tissues of the body, such as skin, cartilage, and the vitreous humour. Therefore, it is well suited to biomedical applications targeting these tissues. The first hyaluronan biomedical product, Healon, was developed in the 1970s and 1980s by Pharmacia, and is approved for use in eye surgery (i.e., corneal transplantation, cataract surgery, glaucoma surgery, and surgery to repair retinal detachment). Other biomedical companies also produce brands of hyaluronan for ophthalmic surgery.
Native hyaluronan has a relatively short half-life (shown in rabbits) so various manufacturing techniques have been deployed to extend the length of the chain and stabilise the molecule for its use in medical applications. The introduction of protein based cross-links, the introduction of free-radical scavenging molecules such as sorbitol, and minimal stabilisation of the HA chains through chemical agents e.g. NASHA stabilisation are all techniques that have been used.
In the late 1970s, intraocular lens implantation was often followed by severe corneal edema, due to endothelial cell damage during the surgery. It was evident that a viscous, clear, physiologic lubricant to prevent such scraping of the endothelial cells was needed.
Due to its high biocompatibility and its common presence in the extracellular matrix of tissues, hyaluronan is gaining popularity as a biomaterial scaffold in tissue engineering research. In particular, a number of research groups have found hyaluronan's properties for tissue engineering and regenerative medicine are significantly improved with crosslinking, producing a hydrogel. This added feature allows a researcher to form a desired shape, as well as to deliver therapeutic molecules, into a host. Hyaluronan can be crosslinked by attaching thiols (trade names: Extracel, HyStem),methacrylates, hexadecylamides (trade name: Hymovis),  and tyramines (trade name: Corgel). Hyaluronan can also be crosslinked directly with formaldehyde (trade name: Hylan-A) or with divinylsulfone (trade name: Hylan-B).
Due to its ability to regulate angiogenesis by stimulating endothelial cells to proliferate, hyaluronic acid can be used to create hydrogels to study vascular morphogenesis. These hydrogels have properties similar to human soft tissue, but are also easily controlled and modified, making HA very suitable for tissue engineering studies. For example, HA hydrogels are appealing for engineering vasculature from endothelial progenitor cells by using appropriate growth factors such as VEGF and Ang-1 to promote proliferation and vascular network formation. Vacuole and lumen formation have been observed in these gels, followed by branching and sprouting through degradation of the hydrogel and finally complex network formation. The ability to generate vascular networks using HA hydrogels leads to opportunities for in vivo and clinical applications. One in vivo study, where HA hydrogels with endothelial colony forming cells were implanted into mice three days after hydrogel formation, saw evidence that the host and engineered vessels joined within 2 weeks of implantation, indicating viability and functionality of the engineered vasculature.
- Hyaluronate Sodium in the ChemIDplus database, consulté le 12 février 2009
- Fraser, J.R.E et al'; Laurent, T. C.; Laurent, U. B. G. (1997). "Hyaluronan: its nature, distribution, functions and turnover" (PDF). Journal of Internal Medicine 242 (1): 27–33. doi:10.1046/j.1365-2796.1997.00170.x. PMID 9260563. Retrieved 2009-06-05.
- Stern, edited by Robert (2009). Hyaluronan in cancer biology (1st ed. ed.). San Diego, CA: Academic Press/Elsevier. ISBN 978-0-12-374178-3.
- Stern R (August 2004). "Hyaluronan catabolism: a new metabolic pathway". Eur J Cell Biol 83 (7): 317–25. doi:10.1078/0171-9335-00392. PMID 15503855.
- Sugahara, K.; N.B. Schwartz and A. Dorfman (1979). "Biosynthesis of hyaluronic acid by Streptococcus". Journal of Biological Chemistry 254 (14): 6252–6261. PMID 376529.
- Wessels, M.R.; A.E. Moses, J.B. Goldberg and T.J. DiCesare (1991). "Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci". PNAS 88 (19): 8317–8321. doi:10.1073/pnas.88.19.8317. PMC 52499. PMID 1656437.
- Schrager, H.M.; J.G. Rheinwald and M.R. Wessels (1996). "Hyaluronic acid capsule and the role of streptococcal entry into keratinocytes in invasive skin infection". Journal of Clinical Investigation 98 (9): 1954–1958. doi:10.1172/JCI118998. PMC 507637. PMID 8903312.
- Rutjes, AW; Jüni, P; da Costa, BR; Trelle, S; Nüesch, E; Reichenbach, S (Aug 7, 2012). "Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis.". Annals of internal medicine 157 (3): 180–91. doi:10.7326/0003-4819-157-3-201208070-00473. PMID 22868835.
- Josefsson, A.; Adamo, H.; Hammarsten, P.; Granfors, T.; Stattin, P. R.; Egevad, L.; Laurent, A. E. M.; Wikström, P.; Bergh, A. (2011). "Prostate Cancer Increases Hyaluronan in Surrounding Nonmalignant Stroma, and This Response is Associated with Tumor Growth and an Unfavorable Outcome". The American Journal of Pathology 179 (4): 1961–1968. doi:10.1016/j.ajpath.2011.06.005. PMC 3181394. PMID 21854754.
- g. Gritsenko, P.; Ilina, O.; Friedl, P. (2012). "Interstitial guidance of cancer invasion". The Journal of Pathology 226 (2): 185–199. doi:10.1002/path.3031. PMID 22006671.
- De Andrés Santos MI, Velasco-Martín A, Hernández-Velasco E, Martín-Gil J, Martín-Gil FJ (1994). "Thermal behaviour of aqueous solutions of sodium hyaluronate from different commercial sources". Thermochim Acta 242: 153–160. doi:10.1016/0040-6031(94)85017-8.
- Shu XZ, Ghosh K, Liu Y, Palumbo FS, Luo Y, Clark RAF, Prestwich GD: Attachment and spreading of fibroblast on an RGD peptide-modified injectable hyaluronan hydrogel. J Biomed Materials Res, 68:365-75, 2004.
- "Hylan G-F 20 (Synvisc) approved by EMEA for pain due to ankle and shoulder OA". National Health Service. Retrieved 2007-07-09.
- Toole, B.P. (August 2000). "Hyaluronan is not just a goo!". Journal of Clinical Investigation 106 (3): 335–336. doi:10.1172/JCI10706. PMC 314333. PMID 10930435.
- Holmes et al. (1988). "Hyaluronic acid in human articular cartilage. Age-related changes in content and size". Biochem J 250 (2): 435–441. PMC 1148875. PMID 3355532.
- Averbeck M et al. (2007) Differential regulation of hyaluronan metabolism in the epidermal and dermal compartments of human skin by UVB irradiation. J Invest Dermatol 127:687–697.
- Glycosaminoglycans of Brain during Development. R. U. Margolis, R. K. Margolis, L. B. Chang, and C. Preti. BIOCHEMISTRY VOL. 14, NO. I , 1975. Pg. 85. Retrieved 1/17/08.
- Meyer K, Hobby GL, Chaffee E, Dawson MH (January 1940). "THE HYDROLYSIS OF HYALURONIC ACID BY BACTERIAL ENZYMES". J Exp Med 71 (2): 137–46. doi:10.1084/jem.71.2.137. PMC 2135078. PMID 19870951.
- Saari H et al. (1993) Differential effects of reactive oxygen species on native synovial fluid and purified human umbilical cord hyaluronate. Inflammation 17:403–415.
- Schulz,T.; Schumacher,U.; Prehm,P. Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J.Biol.Chem.282,20999-21004
- Kakizaki, I.; Kojima, K.; Takagaki, K.; Endo, M.; Kannagi, R.; Ito, M.; Maruo, Y.; Sato, H.; Yasuda, T. et al.; Mita, S; Kimata, K; Itano, N (2004). "A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone". J. Biol. Chem. 279 (32): 33281–33289. doi:10.1074/jbc.M405918200. PMID 15190064.
- Yoshihara, S; Kon, A; Kudo, D; Nakazawa, H; Kakizaki, I; Sasaki, M; Endo, M; Takagaki, K (2005). "A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells". FEBS Letters 579 (12): 2722–6. doi:10.1016/j.febslet.2005.03.079. PMID 15862315.
- Novozymes Biopharma | Produced without the use of animal-derived materials or solvents
- Wayne D. Comper, Extracellular Matrix Volume 2 Molecular Components and Interactions, 1996, Harwood Academic Publishers
- Aruffo A., et al" Cell 1990, 61: 1303–1313
- W. Y. John Chen and Giovanni Abatangelo, Wound Repair and Regeneration, 1999, 7: 79–89
- Kaya G. et al" Genes & Development 1997, 15: 996–1007
- Laurent U. B. G. and Reed R. K. Advanced Drug Delivery Reviews, 1991, 7: 237–256
- Fraser J. R. E. et al" Biochemical Journal 1988, 356: 153–158
- Campbell P. et al" Hepatology 1990, 11: 199–204
- Matou-Nasri, S.; Gaffney, J.; Kumar, S.; Slevin, M. (2009). "Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin". International journal of oncology 35 (4): 761–773. PMID 19724912.
- Yung, S.; Chan, T. M. (2011). "Pathophysiology of the Peritoneal Membrane during Peritoneal Dialysis: The Role of Hyaluronan". Journal of Biomedicine and Biotechnology 2011: 1. doi:10.1155/2011/180594. PMC 3238805. PMID 22203782.
- Tesar, B. M.; Jiang, D.; Liang, J.; Palmer, S. M.; Noble, P. W.; Goldstein, D. R. (2006). "The Role of Hyaluronan Degradation Products as Innate Alloimmune Agonists". American Journal of Transplantation 6 (11): 2622–2635. doi:10.1111/j.1600-6143.2006.01537.x. PMID 17049055.
- Kennndy J. F., et al., HA, Volume 2 Biomedical, Medical and Clinical Aspects, 2002, Woodhead Publishing Limited.
- Wisniewski H. G., et al., The Journal of Immunology, 1996, 156: 1609–1615
- Kobayashi H. and Terao T. American Journal of Physiology, 1997, 276: C1151-1159
- Mohamadzadeh M., et al., The Journal of Clinical Investigation, 1998, 101: 97–108
- Hall C. L., et al., The Journal of cell biology, 1992, 117: 1343–1350
- Wang C. et al., Clinical Cancer Research, 1998, 4: 567–576
- Hall C. L., et al., Oncogene, 1996. 13: 2213–2214
- Morriss-Kay G. M., et al., Journal of Embryology and Experimental Morphology, 1986, 98: 59–70
- Ellis I. R., et al., Experimental Cell Research, 1996, 228: 326–342
- Tammi R., et al., Journal of Investigative Dermatology, 1988, 90: 412–414
- Foschi D., et al., International Journal on Tissue Reaction, 1990, 12: 333–339
- Wisniewski H. G. and Vilcek J. Cytokine & Growth Factor Reviews, 1997, 8: 143–156
- Tammi R, et al., Journal of Investigative Dermatology, 1989, 92: 326–332
- Tuhkanen A-L, et al., Journal of Histochemistry and Cytochemistry, 1998, 46: 241–248
- Kaya G. et al., Genes & Development, 1997, 15: 996–1007
- Longaker M. T., et al., Annals of Surgery, 1991, 213: 292–296
- Baradwaj AG, et al. Spontaneous metastasis of prostate cancer is promoted by excess hyaluornan synthesis and processing. Am J Path. 2009;174:1027–1036
- Bharadwaj AG et al. (2007). "Inducible hyaluornan production reveals differential effects of prostate tumor cell growth and tumor angiogenesis". J Cell Biol 282: 20561–20572. doi:10.1074/jbc.m702964200.
- Gao F, et al. Hyaluronan oligosaccharides are potential stimulators to angiogenesis via RHAMM mediated signal pathway in wound healing. Clinical and Investigative Medicine. 2008;31:E106-116
- Gao, et al. Hypoxia-induced alterations in hyaluronan and hyaluronidase" Adv Exp Med Biol. 2005;566:249–256
- Ouhtit A, et al. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Path. 2007;171:2033–2039
- Naor, et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Sem Cancer Biol. 2008;18:260–267
- Hall CL, et al. Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis. J Neuro-oncology. 1995;103:203–207
- Savani et al. (2001). "Differential involvement of the hyaluornan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis". J Biol Chem 276 (39): 36770–36778. doi:10.1074/jbc.M102273200. PMID 11448954.
-  "Blunt-tip microcannula vs sharp hypodermic needle"
- Lee, J. N. W.; Kim, B. J.; Kim, M. N. M.; Lee, C. K. (2010). "Treatment of Acne Scars Using Subdermal Minimal Surgery Technology". Dermatologic Surgery 36 (8): 1281–1287. doi:10.1111/j.1524-4725.2010.01623.x. PMID 20573176.
- Han, T. E. Y.; Lee, J. N. W.; Lee, J. H. K.; Son, S. J.; Kim, B. J.; Mun, S. K.; Kim, M. N. M.; Lee, C. K. (2011). "Subdermal Minimal Surgery with Hyaluronic Acid as an Effective Treatment for Neck Wrinkles". Dermatologic Surgery 37 (9): 1291–1296. doi:10.1111/j.1524-4725.2011.02057.x. PMID 21635631.
- Frankel, A.; Sohn, A.; Patel, R. V.; Lebwohl, M. (2011). "Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis". Journal of drugs in dermatology : JDD 10 (6): 666–672. PMID 21637908.
- Cox, S. E. E. (2009). "Clinical Experience with Filler Complications". Dermatologic Surgery 35: 1661–1666. doi:10.1111/j.1524-4725.2009.01345.x. PMID 19807761.
- Genitrix HY-50 Vet datasheet
- HY-50 for veterinary use
- Genitrix HY-50 Vet brochure
- Error 404: Page Not Found | Alcon
- Bausch & Lomb: Amvisc and Amvisc Plus – Brief Statement
- Medical Grade Hyaluronan | Lifecore Biomedical
- >Brown TJ; Laurent UBJ Fraser JRE (1991). "Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit". Experimental Physiology 76 (1): 125–134. PMID 2015069.</
- Frampton JE (2010). "Hylan GF-20 Single injection formulation". Drugs Aging 27 (1): 77–85. doi:10.2165/11203900-000000000-00000. PMID 20030435.</
- Anteis | Change starts here
- Medicijnvrije behandeling van artrose en artritis
- 1. Miller D, O'Connor P,William J: Use of Na-Hyaluronate during intraocular lens implantation in rabbits. Ophthal Surg. 8:58–61, 1977
- 7. Miller D, Stegmann R: Healon: A Comprehensive Guide to its Use in Ophthalmic Surgery. J Wiley, NY, 1983
- http://www.biochem.northwestern.edu/ibis/articles/Shea/Segura_et_al_Biomat_2004.pdf doi=10.1016/j.biomaterials.2004.02.067
- Bio-skin FAQ
- Shu XZ, Liu Y, Palumbo FS, Luo Y, Prestwich GD: In situ crosslinkable hyaluronan hydrogels for tissue engineering" Biomaterials 25:1339–1348, 2004.
- Gerecht S, Burdick JA, Ferreira LS, Townsend SA, Langer R, and Vunjak-Novakovic G: Hyaluronic acid hydrogel for controlled self-renewal and differentiation of human embryonic stem cells" Proc Natl Acad Sci USA 104:11298-11303, 2007.
- Smith, M. M.; Russell, A. K.; Schiavinato, A; Little, C. B. (2013). "A hexadecylamide derivative of hyaluronan (HYMOVIS®) has superior beneficial effects on human osteoarthritic chondrocytes and synoviocytes than unmodified hyaluronan". Journal of inflammation (London, England) 10: 26. doi:10.1186/1476-9255-10-26. PMC 3727958. PMID 23889808.
- Dar A, Calabro A: Synthesis and characterization of tyramine-based hyaluronan hydrogels. J Mater Sci: Mater Med, 20:33–44, 2009.
- Wnek GE, Bowlin GL (editors): Encyclopedia of Biomaterials and Biomedical Engineering. Informa Healthcare, 2008.
- Genasetti A, Vigetti D, Viola M, et al (2008). "Hyaluronan and human endothelial cell behavior", Connect Tissue Res, 49(3):120-123.
- Hanjaya-Putra D, Bose V, Shen YI, Yee J, Khetan S, Fox-Talbot K, Steenberg C, Burdick JA and Gerecht S (2011). "Controlled activation of morphogenesis to generate a functional human microvasculature in a synthetic matrix", Blood ,118(3):804-815.
- ATC codes: D03, M09, R01, S01
- Hyaluronan at the US National Library of Medicine Medical Subject Headings (MeSH)
- Hyaluronic acid benefits